NeoStem, Inc. – “Encouraging Findings from PreSERVE AMI”

Nov 19, 2014 (ACCESSWIRE via COMTEX) New York, NY / ACCESSWIRE / November 19, 2014 / NeoStem, Inc. (NASDAQ: NBS) today published a new blog post on The Chairman s Blog, written by the Company s Chief Visionary Officer and Chief Medical Officer of Progenitor Cell Therapy, Dr. Andrew L. Pecora. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends. In his new blog post, Dr. Pecora shared his insights about the initial data for the Phase 2 PreSERVE AMI clinical trial. He commented, We believe the results are encouraging for the feasibility of continuing development of this therapy. Read the full blog post from Dr. Pecora on TheChairmansBlog.com (http://www.thechairmansblog.com/neostem/andrew-pecora/encouraging-findings-preserve-ami/). About NeoStem, Inc. NeoStem is a biopharmaceutical company pursuing the preservation and enhancement of human health globally through th
http://bit.ly/1F3nAiT